Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
BioAtla, Inc. is a biotechnology company focused on developing innovative antibody-drug conjugates (ADCs) for cancer treatment. The company's proprietary technology platform, known as the CAB (Conditionally Active Biologics) platform, enables the selective targeting of tumors while minimizing damage to healthy tissues, providing a competitive edge in the oncology space.
BioAtla's business model is centered around the development of its ADCs, which are designed to deliver cytotoxic agents directly to cancer cells. The company aims to monetize its products through partnerships with larger pharmaceutical firms for commercialization and through potential licensing agreements. Its unique CAB platform provides a competitive advantage by improving the efficacy and safety profile of cancer therapies.
Clinical trial results for lead ADC candidates
Partnership announcements with larger pharmaceutical companies
Regulatory approvals from the FDA for new therapies
Market adoption rates of approved products
Regulatory changes that could impact drug approval processes
Technological disruption in the biotechnology field that could render current platforms obsolete
Emergence of new ADC technologies from competitors
Potential for larger pharmaceutical companies to develop in-house capabilities
High operating losses leading to liquidity concerns
Dependence on external financing for ongoing R&D
low - The biotechnology sector is generally less sensitive to economic cycles as healthcare spending tends to remain stable regardless of economic conditions.
Moderate - Rising interest rates can increase the cost of capital for BioAtla, impacting its ability to fund R&D and clinical trials, which are critical for its growth.
minimal - The company has a negative debt/equity ratio, indicating it is not reliant on debt financing.
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.
high - The stock has demonstrated significant volatility, with a 1-year return of -81.4%.